HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

Benzinga · 03/13 13:21
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.